Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.

Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B, Fischereder M, Jauch KW, Guba M.

Transplantation. 2012 Dec 27;94(12):1208-17. doi: 10.1097/TP.0b013e3182708e56. Review.

PMID:
23269449
2.

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.

Pengel LH, Liu LQ, Morris PJ.

Transpl Int. 2011 Dec;24(12):1216-30. doi: 10.1111/j.1432-2277.2011.01357.x. Epub 2011 Sep 29. Review.

3.

Prevention of cytomegalovirus following solid organ transplantation: a literature review.

Kowalsky S, Arnon R, Posada R.

Pediatr Transplant. 2013 Sep;17(6):499-509. doi: 10.1111/petr.12118. Review.

PMID:
23890075
4.

WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.

Couchoud-Heyer C.

Cochrane Database Syst Rev. 2007 Jul 18;(4):CD001320. Review.

PMID:
17636667
5.

Prevention and treatment of cytomegalovirus infection in organ transplant recipients.

Kusne S, Shapiro R, Fung J.

Transpl Infect Dis. 1999 Sep;1(3):187-203. Review.

PMID:
11428989
6.

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

Strippoli GF, Hodson EM, Jones C, Craig JC.

Transplantation. 2006 Jan 27;81(2):139-45. Review.

PMID:
16436954
7.

Benefits of cytomegalovirus prophylaxis in solid organ transplantation.

Pescovitz MD.

Transplantation. 2006 Jul 27;82(2 Suppl):S4-8. Review.

PMID:
16858270
8.

Management of cytomegalovirus infection and disease after solid-organ transplantation.

van der Bij W, Speich R.

Clin Infect Dis. 2001 Jul 1;33 Suppl 1:S32-7. Review.

PMID:
11389520
9.

Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.

Legendre C, Pascual M.

Clin Infect Dis. 2008 Mar 1;46(5):732-40. doi: 10.1086/527397. Review.

PMID:
18220478
10.
11.

The case for cytomegalovirus prophylaxis in solid organ transplantation.

Snydman DR.

Rev Med Virol. 2006 Sep-Oct;16(5):289-95. Review.

PMID:
16888821
12.

Clinical insights for cancer outcomes in renal transplant patients.

Alberú J.

Transplant Proc. 2010 Nov;42(9 Suppl):S36-40. doi: 10.1016/j.transproceed.2010.07.006. Review.

PMID:
21095450
13.

Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.

Fisher RA.

Transpl Infect Dis. 2009 Jun;11(3):195-202. doi: 10.1111/j.1399-3062.2009.00372.x. Epub 2009 Feb 18. Review.

PMID:
19228345
14.
15.

Indirect effects of cytomegalovirus infection in solid organ transplant recipients.

Pérez-Sola MJ, Castón JJ, Solana R, Rivero A, Torre-Cisneros J.

Enferm Infecc Microbiol Clin. 2008 Jan;26(1):38-47. Review.

PMID:
18208765
16.

Cytomegalovirus infection in solid organ transplantation: economic implications.

Das A.

Pharmacoeconomics. 2003;21(7):467-75. Review.

PMID:
12696987
17.

Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.

Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.

Transplantation. 2012 Jun 15;93(11):1075-85. doi: 10.1097/TP.0b013e31824810e6. Review.

PMID:
22683823
18.

Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.

Murakami N, Riella LV, Funakoshi T.

Am J Transplant. 2014 Oct;14(10):2317-27. doi: 10.1111/ajt.12852. Epub 2014 Aug 21. Review.

19.

Growing experience with mTOR inhibitors in pediatric solid organ transplantation.

Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P, Höcker B, Ahlenstiel T, Kemper M, Brinkert F, Sachse MM, Tönshoff B.

Pediatr Transplant. 2013 Nov;17(7):694-706. doi: 10.1111/petr.12147. Epub 2013 Sep 4. Review.

PMID:
24004351
20.

Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.

Martin JM, Danziger-Isakov LA.

Pediatr Transplant. 2011 May;15(3):229-36. doi: 10.1111/j.1399-3046.2010.01454.x. Epub 2010 Dec 27. Review.

PMID:
21199215

Supplemental Content

Support Center